Fasudil

• UNSPSC Description:

  Fasudil (HA-1077; AT877) is a nonspecific RhoA/ROCK inhibitor and also has inhibitory effect on protein kinases, with an Ki of 0.33 μM for ROCK1, IC50s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, PKG, respectively. Fasudil is also a potent Ca2+ channel antagonist and vasodilator[1][2][3].

• Target Antigen:

  Autophagy; Calcium Channel; PKA; PKC; ROCK

• Type:

  Reference compound

• Related Pathways:

  Autophagy;Cell Cycle/DNA Damage;Cytoskeleton;Epigenetics;Membrane Transporter/Ion Channel;Neuronal Signaling;Stem Cell/Wnt;TGF-beta/Smad

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/fasudil.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=S(C1=CC=CC2=C1C=CN=C2)(N3CCNCCC3)=O

• Molecular Weight:

  291.37

• References & Citations:

  [1]Chen M, et al. Fasudil and its analogs: a new powerful weapon in the long war against central nervous system disorders? Expert Opin Investig Drugs. 2013 Apr;22(4):537-50.|[2]Huang XN, et al. The effects of fasudil on the permeability of the rat blood-brain barrier and blood-spinal cordbarrier following experimental autoimmune encephalomyelitis. J Neuroimmunol. 2011 Oct 28;239(1-2):61-7.|[3]Uehata M, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997 Oct 30;389(6654):990-4.|[4]Fukushima M, et al. Fasudil hydrochloride hydrate, a Rho-kinase (ROCK) inhibitor, suppresses collagen production and enhances collagenase activity in hepatic stellate cells. Liver Int. 2005 Aug;25(4):829-38.|[5]Zhang J, et al. Inhibition of the activity of Rho-kinase reduces cardiomyocyte apoptosis in heart ischemia/reperfusion via suppressing JNK-mediated AIF translocation. Clin Chim Acta. 2009 Mar;401(1-2):76-80.|[6]Sun X, et al. The selective Rho-kinase inhibitor Fasudil is protective and therapeutic in experimental autoimmune encephalomyelitis. J Neuroimmunol. 2006 Nov;180(1-2):126-34. Epub 2006 Sep 22.Adipocyte. 2019 Dec;8(1):114-124. |Br J Cancer. 2023 Mar 23.|Clin Transl Med. 2022 Jul;12(7):e961.|Clin Transl Med. 2022 Oct;12(10):e1036.|Inflammopharmacology. 2023 Apr 19;1-11.|Int J Biol Sci. 2024 Jan 12;20(3):897-915.|J Exp Clin Cancer Res. 2020 Jun 16;39(1):113.|J Pharm Pharmacol. 2021 Mar 29;rgab033.|Neural Regen Res. 2021 Dec;16(12):2512-2520.|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.|SSRN. 2023 Feb 24.|Aging Cell. 2024 Jun 2:e14209.|Aging Cell. 2024 Oct 16:e14366.|Biomed Rep. 2015 May;3(3):361-364. |Cell Mol Immunol. 2023 Mar 2;1-14.|Eur J Pharmacol. 2024 May 13:975:176640.|Sci Rep. 2018 Feb 6;8(1):2477. |Transl Neurosci. 2020 Apr 20;11(1):75-86.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Launched

• CAS Number:

  103745-39-7